# US 2016/0258947 A1 · Compositions for classifying a human pediatric subject having adolescent idiopathic scoliosis (ais)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258947 A1
- Document ID: US20160258947A1
- Status: Published application
- Kind: A1
- Application number: 15/159,222
- Filed: 2016-05-19
- Published: 2016-09-08
- Earliest claimed: 2002-02-28
- Assignees: Chu Sainte-Justine
- Applicants: Chu Sainte-Justine
- Inventors: ALAIN MOREAU
- Web page: https://patentgrep.com/patent/US20160258947A1

## CPC

- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C12Q 1/02: involving viable microorganisms
- C12Q 1/527: involving lyase
- G01N 33/56966: {Animal cells}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/726: G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G01N 2800/10: Musculoskeletal or connective tissue disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A composition for classifying a human pediatric subject having adolescent idiopathic scoliosis (AIS), comprising (a) a cell sample of the subject; and (b) a known melatonin-signaling pathway agonist, wherein said melatonin signaling pathway in said cell sample has been artificially induced by said melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and whereby the composition enables the detection of the presence or absence of at least one impairment in the melatonin-signaling pathway in cells from said cell sample and thereby enables the classification of subject.

## Claims

### Claim 1

A composition for classifying a human pediatric subject having adolescent idiopathic scoliosis (AIS), comprising (a) a cell sample of the subject; and (b) a known melatonin-signaling pathway agonist, wherein said melatonin signaling pathway in said cell sample has been artificially induced by said melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and whereby the composition enables the detection of the presence or absence of at least one impairment in the melatonin-signaling pathway in cells from said cell sample and thereby enables the classification of subject.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said cell sample is a blood cell sample selected from the group consisting of lymphocyte cell sample and monocyte cell sample.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said cell sample is a lymphocyte cell sample.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said cell sample is a monocyte cell sample.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is a melatonin analog.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is melatonin.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is a GTP analog.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is GTP.

### Claim 9 (depends on 1)

The composition of claim 1, further comprising a known activator of adenylyl cyclase.

### Claim 10 (depends on 9)

The composition of claim 9, wherein said known activator of adenylyl cyclase is forskolin.

### Claim 11 (depends on 1)

The composition of claim 1, further comprising artificial bone or dentin matrix, wherein said sample is an osteoclast cell sample.

### Claim 12 (depends on 1)

The composition of claim 1, further comprising [3H]-thymidine, wherein said cell sample is an osteoblast cell sample.

### Claim 13

A composition for classifying a human pediatric subject having idiopathic scoliosis (AIS), comprising (a) a lysed cell sample of the subject; and (b) reagents for detecting cAMP accumulation, wherein, prior to being lysed, said cell sample has been contacted with a known activator of adenylyl cyclase to artificially induce Cyclic Adenosine Monophosphate (cAMP) accumulation and subsequently with a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and whereby the composition enables the detection of the presence or absence of at least one impairment in the melatonin-signaling pathway in cells from said cell sample and thereby enables the classification of the subject.

### Claim 14 (depends on 13)

The composition of claim 13, wherein said known activator of adenylyl cyclase is forskolin.

### Claim 15 (depends on 13)

The composition of claim 13, wherein said known melatonin-signaling pathway agonist is a melatonin analog.

### Claim 16 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is melatonin.

### Claim 17 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is a GTP analog.

### Claim 18 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is GTP.

### Claim 19 (depends on 1)

The composition of claim 1, wherein said reagents for detecting cAMP comprises an antibody which binds to cAMP.

### Claim 20 (depends on 1)

The composition of claim 1, wherein said known melatonin-signaling pathway agonist is at a pharmacological concentration

### Claim 21 (depends on 21)

The composition of claim 21, wherein said cell sample has been contacted with a pharmacological concentration of said know melatonin-signaling pathway agonist.

### Claim 22 (depends on 1)

The composition of claim 1, further comprising an antibiotic.
